Oncology Nurse Edition Subscriptions Header

Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”